ImmunoGen, Inc. Announces Presentation Of Favorable SAR3419 Interim Clinical Data At ASCO
Links shared publicly online about this topic.
- 239total visits
ImmunoGen, Inc. Announces Presentation Of Favorable SAR3419 Interim Clinical Data At ASCO
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload (TAP) technology, today
View full resource at medicalnewstoday.com
Tags: Cancer, Leukemia, Lymphoma, Biotech
Most Recently Shared on June 6, 2011 at 9:05 pm By:
ImmunoGen, Inc. Announces Presentation Of Favorable SAR3419 Interim Clinical Data At ASCO http://mnt.to/3WNn #cancer
Also Shared By:
Advertisement
MNT Leukemia
@mnt_leukemia
ImmunoGen, Inc. Announces Presentation Of Favorable SAR3419 Interim Clinical Data At ASCO http://mnt.to/3WNn #lymphoma #leukemia
1 year ago...